You are here: Industry Insights > NICE

News List

NICE backs AZ' Calquence for chronic lymphocytic leukaemia pharmatimes
December 09, 2020
The National Institute for Health and Care Excellence has published preliminary guidelines backing use of AstraZeneca's Calquence (acalabrutinib) as an NHS funded treatment for chronic lymphocytic leukaemia (CLL).
NICE turns down Novartis' Adakveo pharmatimes
November 30, 2020
Novartis' Adakveo (crizanlizumab) has hit a setback having failed to gain acceptance by the National Institute for Health and Care Excellence (NICE).
NICE backs use of new treatment for multiple myeloma pharmatimes
November 27, 2020
Patients with a difficult to treat form of multiple myeloma will now gain access to a new treatment on the NHS in England and Wales, after cost regulators issued final guidance on the use of Sanofi's Sarclisa (isatuximab).
NICE backs Braftovi for BRAF-positive colorectal cancer pharmatimes
November 25, 2020
The National Institute for Health and Care Excellence (NICE) has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF-positive metastatic colorectal cancer.
Potential anti-COVID-19 nasal spray developed by researchers europeanpharmaceuticalreview
November 23, 2020
A new nasal spray with ingredients already approved for use in humans could be used to protect people against COVID-19.
NICE recommends Lilly’s migraine med Emgality pharmatimes
November 20, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Emgality as a preventative treatment for migraine in adults with episodic and chronic migraine.
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment europeanpharmaceuticalreview
November 16, 2020
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
NICE green light for Cablivi in rare blood-clotting disorder pharmatimes
November 16, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has given a green light to Sanofi’s Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) – a rare and potentially life-threatening blood clotting disorder.
AbbVie’s Venclyxto gets NICE blood cancer backing pharmatimes
November 12, 2020
AbbVie’s Venclyxto (venetoclax) has been recommended for use by the National Institute of Health and Care Excellence (NICE) as a routine treatment for chronic lymphocytic leukaemia (CLL).
NICE rules nivolumab is not cost effective for use on NHS europeanpharmaceuticalreview
November 10, 2020
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page